A growing number of congressional lawmakers are urging the Trump administration to reconsider a federal rule set to take effect next month. Critics warn the regulation will prevent Americans from obtaining prescription medicines from licensed international pharmacies. The pending rule mandates that medicines mailed from abroad pass through a specific customs process requiring a licensed customs broker and a financial guarantee known as an entry bond. These new requirements add both burden and cost for individuals who have historically received prescriptions from Canada and other countries to save money on expensive drugs. The demand for such imports emerged two decades ago as medication prices rose, leading some Americans to travel by bus to Canada for cheaper alternatives. Under current law, importing medicine into the U.S. for personal use is generally illegal because the drugs often lack approval from the U.S. Food and Drug Administration as safe and effective.